comparemela.com

Latest Breaking News On - Affinia therapeutics - Page 11 : comparemela.com

Chutes & Ladders—Zimmer Biomet calls on Medtronic vet Jamali to lead spinout

Samir Mody as chief commercial officer, while  Friedrich Asmus signs on as SVP, clinical development and medical affairs. Meanwhile, the company has also tapped  Joel Centeno as SVP, manufacturing, quality and supply chain. Mody comes over from Medtronic, where he was vice president, CRHF strategy, health economics and reimbursement. Asmus previously served as VP of clinical development at ophthalmology biotech ProQR Therapeutics, while Centeno comes over after stints at Boston Scientific, Hologic and AltheaDx. > Antios Therapeutics has tapped  Tamra Adams as chief financial officer, a newly created executive position at the company. Before joining Antios, Adams founded Accounting Concepts, which provided CFO, accounting, and financial services to emerging growth companies in the biopharmaceutical and information technology industries, including Engage Therapeutics.

Boston
Massachusetts
United-states
Cambridge
Cambridgeshire
United-kingdom
Canada
Matteo-levisetti
Aeglea-biotherapeutics
Fraiser-kansteiner
Friedrich-asmus
Tamra-adams

Affinia Therapeutics Announces Addition of Gene Therapy Scientific and Medical Experts to Leadership Team to Advance Novel Gene Therapy Platform and Programs to the Clinic

Home / Top News / Affinia Therapeutics Announces Addition of Gene Therapy Scientific and Medical Experts to Leadership Team to Advance Novel Gene Therapy Platform and Programs to the Clinic Affinia Therapeutics Announces Addition of Gene Therapy Scientific and Medical Experts to Leadership Team to Advance Novel Gene Therapy Platform and Programs to the Clinic Gene editing expert Charles Albright, Ph.D., joins as chief scientific officer Gene therapy development expert Petra Kaufmann, M.D.,  joins as chief medical officer – WALTHAM, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases, today announced the completion of its leadership team. Collectively, the executives represent a diverse team of proven leaders in gene therapy who have successfully developed novel platforms and translated the

United-states
California
North-carolina
Bonn
Nordrhein-westfalen
Germany
San-francisco
Luk-vandenberghe
Laura-richman
Rob-may
Charles-albright
Botond-roska

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.